

October 20, 2015

Theravance to Report Third Quarter 2015 Financial Results on October 28, 2015

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 10/20/15 -- Theravance, Inc. (NASDAQ: THRX) announced today that it will release financial results for the quarter ended September 30, 2015 after market close on Wednesday, October 28, 2015.

An accompanying conference call will be held at 5:00 p.m. Eastern Daylight Time. To participate in the live call by telephone, please dial (877) 837-3908 from the U.S., or (973) 890-8166 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting Theravance's website at www.thrxinc.com. To listen to the live call via the Internet, please go to the website 15 minutes prior to its start to register, download, and install any necessary audio software.

A replay of the conference call will be available on Theravance's website for 30 days through November 27, 2015. An audio replay will also be available through 11:59 p.m. Eastern Standard Time on November 4, 2015 by dialing (855) 859-2056 from the U.S., or (404) 537-3406 for international callers, and entering confirmation code 61360060.

About Theravance

Theravance, Inc. is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Theravance's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Theravance and GSK. Under the agreement with GSK, Theravance is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Theravance retains a 15% economic interest in future payments made by GSK for earlier-stage programs under the agreements with GSK. For more information, please visit Theravance's website at www.thrxinc.com.

ANORO®, RELVAR®, BREO® and ELLIPTA® are trade marks of the GlaxoSmithKline group of companies.

(THRX-F)

Contact Information:

Investor Relations

Eric d'Esparbes

+1 650 238 9640

investor.relations@thrxinc.com

Source: Theravance, Inc.

News Provided by Acquire Media